From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. HIV/AIDS Clinical Care>
  4. Meetings

HIV/AIDS Clinical Care: Meetings

Some content may require paid access to the site. Subscribe or purchase a seven-day site pass for the full text of all our clinical perspectives on medical journal articles, guidelines, and news.


to
Items 1-10 of 142 are shown

Report from the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention

Our physician-editors detail the most important findings from this year's meeting

Early ART Initiation Improves Survival in Resource-Limited Settings

New findings from Haiti (described at IAS 2009) support starting ART when CD4 counts fall below 350 cells/mm3 — the same threshold that is recommended in resource-rich settings.

Maternal ART Reduces Transmission of HIV through Breast-Feeding

In a study conducted in Botswana (and reported at IAS 2009), the rate of mother-to-child transmission was only 1% among breast-feeding women who received ART through 6 months postpartum.

Nevirapine vs. Boosted Atazanavir — The ARTEN Study

The combination of nevirapine + tenofovir + FTC (or 3TC) is safe and effective in treatment-naive patients, according to data presented at IAS 2009.

GSK572 — A "Next-Generation" Integrase Inhibitor?

Early data presented at IAS 2009 are encouraging.

Abacavir and CVD — Again

One large study presented at IAS 2009 supported an association between abacavir and cardiovascular risk, but another did not.

Strategies for Antiretroviral Deintensification

Data presented at IAS 2009 highlighted new approaches to PI therapy for patients with virologic suppression, including simplifying ritonavir-boosted atazanavir to unboosted atazanavir and trying to sustain suppression using darunavir without nucleosides. Success rates differed among these strategies.

ALTAIR — The End of NRTI-Only Regimens

In a randomized study, standard combination therapy was preferable to a quadruple-NRTI regimen in terms of both virologic control and adverse effects.

Report from the XVIII International HIV Drug Resistance Workshop

An expert's take on the most clinically relevant reports from this year's resistance meeting

No Clinical Benefit from Adding IL-2 to ART

In two large trials presented at CROI 2009, CD4-cell increases were greater with IL-2 and ART together than with ART alone, but these increases did not lead to reductions in morbidity or mortality.

Items 1-10 of 142 are shown

to

Search

Advanced

Sign-In

Forgot your password?

New to Journal Watch?





Copyright © 2009. Massachusetts Medical Society. All rights reserved.